Artivion Amends Credit Facility and Option Purchase Agreements with Endospan for Nexus Stent Graft System

Artivion, a leading medical technology company, has recently announced the amendment of its credit facility and option purchase agreements with Endospan, the developer of the Nexus stent graft system. The Nexus is the first and only branched endovascular system that has been approved by the US Food and Drug Administration (FDA) to treat aortic arch disease, including both aortic aneurysms and dissections.

Minimally Invasive Treatment for Aortic Arch Disease Patients

Aortic arch disease patients with aneurysms or dissections who receive treatment have previously had little choice but to undergo open-chest surgery with its associated invasiveness and risks, lengthy hospitalizations, and prolonged recuperation. The Nexus stent graft system is a game-changer in the treatment of aortic arch disease as it transforms a complex surgical aortic arch repair into a minimally invasive endovascular procedure.

While minimally invasive endovascular repair has been the standard of care for abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA), the arrival of the Nexus stent graft system provides a new and effective choice of treatment for aortic arch disease. According to Artivion, this innovation addresses an annual global addressable market opportunity of US$600 million, according to the latest estimates.

The Benefits of the Nexus Stent Graft System

The Nexus stent graft system offers several advantages over traditional open-chest surgery. It is a minimally invasive procedure that requires a smaller incision, resulting in less postoperative pain and a quicker recovery time. The Nexus stent graft system is also less risky than open-chest surgery since there is less chance of bleeding, infection, or other complications. Patients who receive this treatment can expect to recover faster and with fewer complications.

Investment in the Next Frontier of Aortic Arch Surgery

Artivion views its revised credit facility and option purchase agreements with Endospan as an investment in the next frontier of aortic arch surgery. Should Artivion exercise its option to acquire Endospan, it believes it will be able to meaningfully expand its total addressable market at that time on terms more favorable than existed prior to these amendments. This strategic investment will further solidify Artivion’s position as a global leader in aortic repair.

Conclusion

The Nexus stent graft system is a significant innovation for the treatment of aortic arch disease. This minimally invasive endovascular procedure provides patients with a less dangerous, less painful, and quicker postoperative recovery time. With the help of Artivion, Endospan can bring this groundbreaking technology to patients around the world, giving them access to the latest and most innovative treatments available for aortic arch disease.

Originally Post From https://vascularnews.com/artivion-amends-agreements-with-endospan/

Read more about this topic at
The Nexus Revolution, Part 1: The Technical Foundation …
GWSO to Unveil Revolutionary TrinityPower Nexus System …